Table 4.

Sensitivity analyses

Comparing methods for identifying omalizumab responders	Most cost-effective alternative	Threshold
Likelihood that omalizumab candidate will be identified as an omalizumab responder via a trial of omalizumab therapy: 0.468	FeNO measurement + omalizumab trial	No threshold
Likelihood that omalizumab candidate will be identified as an omalizumab responder via a trial of omalizumab therapy: 0.633	No threshold
Likelihood that omalizumab candidate will have FeNO >19.5 ppb: 0.434	FeNO measurement + omalizumab trial	No threshold
Likelihood that omalizumab candidate will have FeNO >19.5 ppb: 0.587	No threshold
Likelihood that patient predicted to be an omalizumab responder (FeNO >19.5 ppb) will be confirmed as an omalizumab responder following a trial of therapy: 0.850	FeNO measurement + omalizumab trial	No threshold
Likelihood that patient predicted to be an omalizumab responder (FeNO >19.5 ppb) will be confirmed as an omalizumab responder following a trial of therapy: 1.000	No threshold

Abbreviation: FeNO, fractional exhaled nitric oxide.